Nonreplicating Influenza A Virus Vaccines Confer Broad Protection Against Lethal Challenge

Overview

Journal mBio

Publisher American Society for Microbiology

Specialty Microbiology

Date 2015 Oct 23

PMID 26489862

Citations 38

Authors

Mariana Baz

Kobporn Boonnak

Myeisha Paskel

Celia Santos

Timothy Powell

Alain Townsend

Kanta Subbarao

Affiliations

Soon will be listed here.

Abstract

Unlabelled: New vaccine technologies are being investigated for their ability to elicit broadly cross-protective immunity against a range of influenza viruses. We compared the efficacies of two intranasally delivered nonreplicating influenza virus vaccines (H1 and H5 S-FLU) that are based on the suppression of the hemagglutinin signal sequence, with the corresponding H1N1 and H5N1 cold-adapted (ca) live attenuated influenza virus vaccines in mice and ferrets. Administration of two doses of H1 or H5 S-FLU vaccines protected mice and ferrets from lethal challenge with homologous, heterologous, and heterosubtypic influenza viruses, and two doses of S-FLU and ca vaccines yielded comparable effects. Importantly, when ferrets immunized with one dose of H1 S-FLU or ca vaccine were challenged with the homologous H1N1 virus, the challenge virus failed to transmit to naive ferrets by the airborne route. S-FLU technology can be rapidly applied to any emerging influenza virus, and the promising preclinical data support further evaluation in humans.

Importance: Influenza viruses continue to represent a global public health threat, and cross-protective vaccines are needed to prevent seasonal and pandemic influenza. Currently licensed influenza vaccines are based on immunity to the hemagglutinin protein that is highly variable. However, T cell responses directed against highly conserved viral proteins contribute to clearance of the virus and confer broadly cross-reactive and protective immune responses against a range of influenza viruses. In this study, two nonreplicating pseudotyped influenza virus vaccines were compared with their corresponding live attenuated influenza virus vaccines, and both elicited robust protection against homologous and heterosubtypic challenge in mice and ferrets, making them promising candidates for further evaluation in humans.

Citing Articles

A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.

Sadler H, Rijal P, Tan T, Townsend A J Virol. 2025; 99(2):e0033124.

PMID: 39868800 PMC: 11853075. DOI: 10.1128/jvi.00331-24.

Intranasal Delivery of Saponin-Based Nanoadjuvants Improve Humoral Immune Response of Influenza Vaccine in Aged Mice.

Silveira F, Garcia F, Garcia G, Chabalgoity J, Rossi S, Baz M Vaccines (Basel). 2024; 12(8).

PMID: 39204028 PMC: 11360193. DOI: 10.3390/vaccines12080902.

Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada.

Rabezanahary H, Gilbert C, Santerre K, Scarrone M, Gilbert M, Theriault M Heliyon. 2024; 10(10):e31026.

PMID: 38826717 PMC: 11141348. DOI: 10.1016/j.heliyon.2024.e31026.

Single-cycle influenza virus vaccine generates lung CD8 Trm that cross-react against viral variants and subvert virus escape mutants.

Zheng M, Tan T, Villalon-Letelier F, Lau H, Deng Y, Fritzlar S Sci Adv. 2023; 9(36):eadg3469.

PMID: 37683004 PMC: 10491285. DOI: 10.1126/sciadv.adg3469.

nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice.

Silveira F, Rivera-Patron M, Deshpande N, Sienra S, Checa J, Moreno M Front Immunol. 2023; 14:1163858.

PMID: 37197659 PMC: 10183569. DOI: 10.3389/fimmu.2023.1163858.

References

Martinez-Sobrido L, Cadagan R, Steel J, Basler C, Palese P, Moran T . Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol. 2009; 84(4):2157-63. PMC: 2812370. DOI: 10.1128/JVI.01433-09. View

Rimmelzwaan G, Sutter G . Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines. 2009; 8(4):447-54. PMC: 9709929. DOI: 10.1586/erv.09.4. View

Price G, Soboleski M, Lo C, Misplon J, Quirion M, Houser K . Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One. 2010; 5(10):e13162. PMC: 2953831. DOI: 10.1371/journal.pone.0013162. View

Chen G, Lau Y, Lamirande E, McCall A, Subbarao K . Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc Natl Acad Sci U S A. 2011; 108(3):1140-5. PMC: 3024675. DOI: 10.1073/pnas.1009908108. View

Bandell A, Woo J, Coelingh K . Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines. 2011; 10(8):1131-41. DOI: 10.1586/erv.11.73. View

Soboleski M, Gabbard J, Price G, Misplon J, Lo C, Perez D . Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One. 2011; 6(7):e21937. PMC: 3137593. DOI: 10.1371/journal.pone.0021937. View

Lakdawala S, Lamirande E, Suguitan Jr A, Wang W, Santos C, Vogel L . Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus. PLoS Pathog. 2012; 7(12):e1002443. PMC: 3248560. DOI: 10.1371/journal.ppat.1002443. View

Lillie P, Berthoud T, Powell T, Lambe T, Mullarkey C, Spencer A . Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012; 55(1):19-25. PMC: 3369564. DOI: 10.1093/cid/cis327. View

Powell T, Silk J, Sharps J, Fodor E, Townsend A . Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity. J Virol. 2012; 86(24):13397-406. PMC: 3503098. DOI: 10.1128/JVI.01820-12. View

10.

Lambe T, Carey J, Li Y, Spencer A, van Laarhoven A, Mullarkey C . Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci Rep. 2013; 3:1443. PMC: 3595699. DOI: 10.1038/srep01443. View

11.

Yang C, Skiena S, Futcher B, Mueller S, Wimmer E . Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc Natl Acad Sci U S A. 2013; 110(23):9481-6. PMC: 3677463. DOI: 10.1073/pnas.1307473110. View

12.

Baker S, Guo H, Albrecht R, Garcia-Sastre A, Topham D, Martinez-Sobrido L . Protection against lethal influenza with a viral mimic. J Virol. 2013; 87(15):8591-605. PMC: 3719819. DOI: 10.1128/JVI.01081-13. View

13.

Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W . Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013; 19(10):1305-12. DOI: 10.1038/nm.3350. View

14.

van de Sandt C, Kreijtz J, de Mutsert G, Geelhoed-Mieras M, Hillaire M, Vogelzang-van Trierum S . Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol. 2013; 88(3):1684-93. PMC: 3911609. DOI: 10.1128/JVI.02843-13. View

15.

Jin H, Subbarao K . Live attenuated influenza vaccine. Curr Top Microbiol Immunol. 2014; 386:181-204. DOI: 10.1007/82_2014_410. View

16.

Coughlan L, Mullarkey C, Gilbert S . Adenoviral vectors as novel vaccines for influenza. J Pharm Pharmacol. 2015; 67(3):382-99. DOI: 10.1111/jphp.12350. View

17.

Wang Z, Wan Y, Chenli Qiu , Quinones-Parra S, Zhu Z, Loh L . Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8⁺ T cells. Nat Commun. 2015; 6:6833. PMC: 4479016. DOI: 10.1038/ncomms7833. View

18.

Hayward A, Wang L, Goonetilleke N, Fragaszy E, Bermingham A, Copas A . Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. Am J Respir Crit Care Med. 2015; 191(12):1422-31. PMC: 4476562. DOI: 10.1164/rccm.201411-1988OC. View

19.

Belyakov I, Ahlers J . What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J Immunol. 2009; 183(11):6883-92. DOI: 10.4049/jimmunol.0901466. View

20.

Chen Z, Wang W, Zhou H, Suguitan Jr A, Shambaugh C, Kim L . Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol. 2009; 84(1):44-51. PMC: 2798434. DOI: 10.1128/JVI.02106-09. View